![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=150&resize=150,150&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
Driving Clean Energy Forward: SANY R.E. Marks Milestone in Europe with Serbia’s Alibunar Wind Power Project
BEIJING, June 10, 2025 /PRNewswire/ -- As the global spotlight turns once…
Biometric passport for the DR Congo – implemented with DERMALOG as system partner
The Democratic Republic of the Congo officially introduced its new biometric passport…
MemeCore Announces Strategic Entry into South Korea with Acquisition of KOSDAQ-Listed Company
SEOUL, South Korea, June 5, 2025 /PRNewswire/ -- MemeCore, the world's first…
Innovation in Abu Dhabi: The Venom Blockchain Revolution Begins
ABU DHABI, UAE, April 9, 2024 /CNW/ -- Marking a milestone in the technology…
